|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,742.00 MXN | +0.62% |
|
+0.62% | +9.68% |
| 08:43am | Novartis Wins Canadian Approval for Immunoglobulin A Nephropathy Treatment | MT |
| 14/07 | Novartis' Vanrafia Wins Health Canada Approval for IgA Nephropathy | MT |
| Market Cap | 28TCr 4,91200Cr 25TCr 23TCr 21TCr 40TCr 26,86900Cr 40TCr 2,71800Cr 1,06600Cr 13,19500Cr 1,05400Cr 1,03100Cr 45,56800Cr | P/E 2026 * |
21.4x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 31TCr 5,47300Cr 27TCr 25TCr 23TCr 44TCr 29,93400Cr 45TCr 3,02800Cr 1,18800Cr 14,70000Cr 1,17400Cr 1,14900Cr 50,76600Cr | EV / Sales 2026 * |
5.5x | EV / Sales 2027 * | 5.13x |
| Free-Float |
91.66% | Yield 2026 * |
2.87% | Yield 2027 * | 2.97% |
Last Transcript: Novartis AG
| 1 day | +0.62% | ||
| 1 week | +0.62% | ||
| Current month | +0.62% | ||
| 1 month | +5.42% | ||
| 3 months | +2.81% | ||
| 6 months | +7.28% | ||
| Current year | +9.68% |
| 1 month | 2,563 |  | 2,742 |
| Current year | 2,479 | | 2,866.83 |
| 1 year | 2,206 | | 2,866.83 |
| 3 years | 1,540 | | 2,866.83 |
| 5 years | 1,520 | | 2,866.83 |
| 10 years | 1,320.81 | | 2,866.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.62% | +0.62% | - | - | 28TCr | |
| -0.56% | -1.52% | +49.04% | +171.88% | 1,06000Cr | |
| +0.31% | -0.60% | +64.29% | +62.31% | 62TCr | |
| -0.03% | -2.65% | +28.86% | +85.64% | 44TCr | |
| -1.75% | -0.33% | +28.78% | +23.58% | 33TCr | |
| -1.75% | -10.57% | +20.67% | +22.07% | 27TCr | |
| +0.67% | +1.03% | -26.10% | -37.96% | 22TCr | |
| -0.81% | -1.63% | +22.07% | +58.33% | 20TCr | |
| +1.21% | +1.38% | +19.85% | +71.29% | 16TCr | |
| +1.28% | +3.20% | -4.56% | -32.11% | 14TCr | |
| Average | -0.03% | -1.66% | +22.54% | +47.23% | 38.11TCr | |
| Weighted average by Cap. | -0.18% | -1.84% | +35.19% | +82.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.68TCr 99TCr 4.99TCr 4.62TCr 4.25TCr 8.04TCr 5,44100Cr 8.19TCr 55TCr 22TCr 2,67200Cr 21TCr 21TCr 9,22800Cr | 6.03TCr 1,05500Cr 5.29TCr 4.9TCr 4.51TCr 8.52TCr 5,76900Cr 8.69TCr 58TCr 23TCr 2,83300Cr 23TCr 22TCr 9,78300Cr |
| Net income | 1.41TCr 25TCr 1.23TCr 1.14TCr 1.05TCr 1.99TCr 1,34800Cr 2.03TCr 14TCr 5.35TCr 66TCr 5.29TCr 5.17TCr 2,28500Cr | 1.56TCr 27TCr 1.37TCr 1.27TCr 1.17TCr 2.21TCr 1,49700Cr 2.25TCr 15TCr 5.94TCr 74TCr 5.87TCr 5.75TCr 2,53900Cr |
| Net Debt | 3.2TCr 56TCr 2.81TCr 2.6TCr 2.39TCr 4.53TCr 3,06500Cr 4.62TCr 31TCr 12TCr 1,50500Cr 12TCr 12TCr 5,19800Cr | 2.85TCr 50TCr 2.5TCr 2.32TCr 2.13TCr 4.03TCr 2,73100Cr 4.11TCr 28TCr 11TCr 1,34100Cr 11TCr 10TCr 4,63200Cr |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
- NVS N Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
